[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

July 2019 - April 2016

Decade

Year

Issue

December 2017, Vol 2, No. 12, Pages 1291-1404

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1291. doi:10.1001/jamacardio.2016.3679
Original Investigation

Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation: Insights and Results From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study Pooled Analysis

Abstract Full Text
free access has audio
JAMA Cardiol. 2017;2(12):1303-1313. doi:10.1001/jamacardio.2017.3802

This pooled analysis study examines 1-year outcomes in women and minorities vs white men following percutaneous coronary intervention with everolimus-eluting stents.

Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials

Abstract Full Text
free access has active quiz
JAMA Cardiol. 2017;2(12):1315-1321. doi:10.1001/jamacardio.2017.3983

This study examines the strength of association between a prior, a current, or a change in Kansas City Cardiomyopathy Questionnaire scores with death and hospitalization in patients with preserved and reduced ejection fractions using.

Role of Hospital Volumes in Identifying Low-Performing and High-Performing Aortic and Mitral Valve Surgical Centers in the United States

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1322-1331. doi:10.1001/jamacardio.2017.4003

This study uses the AHRQ NIS data set to examine the association of hospital procedure volume with hospital performance for aortic and mitral valve surgical procedures.

Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1332-1340. doi:10.1001/jamacardio.2017.4191

This cohort study compares improvement in prognostication of long-term incident coronary heart disease and atherosclerotic cardiovascular disease using coronary artery calcium scores among individuals with diabetes, metabolic syndrome, or neither condition who participated in the Multi-Ethnic Study of Atherosclerosis.

Racial Differences in Prevalence and Risk for Intracranial Atherosclerosis in a US Community-Based Population

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1341-1348. doi:10.1001/jamacardio.2017.4041

This cohort study examines differences in the prevalence of and risk for intracranial atherosclerotic disease between black and white men and women.

Association of Physical Activity With Risk of Major Cardiovascular Diseases in Chinese Men and Women

Abstract Full Text
open access
JAMA Cardiol. 2017;2(12):1349-1358. doi:10.1001/jamacardio.2017.4069

This prospective study explores the association between higher levels of physical activity and all major subtypes of cardiovascular disease in Chinese men and women.

Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1361-1368. doi:10.1001/jamacardio.2017.3882

This study tests the hypothesis that patients with borderline pulmonary hypertension have decreased survival compared with patients with lower mean pulmonary arterial pressure and frequently develop overt pulmonary hypertension.

Brief Report

Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1369-1374. doi:10.1001/jamacardio.2017.3655

This study used a Markov decision model to determine the cost-effectiveness of a PCSK9 inhibitor and statin treatment strategy compared with a statin-alone strategy, using results of the FOURIER trial.

Feasibility, Process, and Outcomes of Cardiovascular Clinical Trial Data Sharing: A Reproduction Analysis of the SMART-AF Trial

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1375-1379. doi:10.1001/jamacardio.2017.3808

This study evaluates the feasibility, process, and outcomes of a reproduction analysis of the SMART-AF trial using shared clinical trial data..

Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1380-1384. doi:10.1001/jamacardio.2017.3868

This randomized clinical trial evaluates whether chewing a loading dose of ticagrelor, 180 mg, vs traditional oral administration of an equal dose enhances platelet inhibition at 30 minutes and 1 hour after loading dose administration in patients with ST-segment elevation myocardial infarction.

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Abstract Full Text
open access
JAMA Cardiol. 2017;2(12):1385-1391. doi:10.1001/jamacardio.2017.3944

This secondary analysis of a randomized clinical trial compares outcomes of evolocumab and placebo for subgroups of patients with stable atherosclerotic cardiovascular disease.

Viewpoint

The Imminent Demise of Cardiovascular Drug Development

Abstract Full Text
JAMA Cardiol. 2017;2(12):1293-1294. doi:10.1001/jamacardio.2017.3753

This Viewpoint compares the robustness of cancer drug development with the decline of cardiovascular drug development and evaluates how pricing models affect each.

Resuscitating Cardiovascular Drug Development

Abstract Full Text
JAMA Cardiol. 2017;2(12):1295-1296. doi:10.1001/jamacardio.2017.3756

This Viewpoint gives reasons why cardiovascular drug development has stalled in recent years and proposes options for lowering the regulatory, financial, and scientific barriers to cardiovascular drug development.

From the Heart

What Becomes of the Brokenhearted

Abstract Full Text
JAMA Cardiol. 2017;2(12):1297. doi:10.1001/jamacardio.2017.2270
Editorial

Cost-effectiveness of PCSK9 Inhibitors: Proof in the Modeling

Abstract Full Text
JAMA Cardiol. 2017;2(12):1298-1299. doi:10.1001/jamacardio.2017.3656

What Constitutes Experience in Surgical Treatment of Valve Disease and How Important Is It?

Abstract Full Text
JAMA Cardiol. 2017;2(12):1299-1300. doi:10.1001/jamacardio.2017.4004

Death by Gun Violence—A Public Health Crisis

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1301-1302. doi:10.1001/jamacardio.2017.4413
Invited Commentary

Physical Activity to Prevent Cardiovascular Disease: A Simple, Low-Cost, and Widely Applicable Approach for All Populations

Abstract Full Text
JAMA Cardiol. 2017;2(12):1358-1360. doi:10.1001/jamacardio.2017.4070

Are Cholesterol Treatment Targets a Deterrent to Optimal Lipid-Lowering Therapy?

Abstract Full Text
JAMA Cardiol. 2017;2(12):1392-1393. doi:10.1001/jamacardio.2017.3943
JAMA Cardiology Clinical Challenge

A 52-Year-Old Man With Unheralded Syncope

Abstract Full Text
has active quiz
JAMA Cardiol. 2017;2(12):1394-1395. doi:10.1001/jamacardio.2017.2425

A 52-year-old man with mild asthma who experienced an episode of unheralded syncope while walking has sinus bradycardia and first-degree atrioventricular, left posterior fascicle, and right bundle branch blocks on electrocardiography. What is your diagnosis?

Comment & Response

Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When Is the Most Clinically Relevant Time to Evaluate?

Abstract Full Text
JAMA Cardiol. 2017;2(12):1397. doi:10.1001/jamacardio.2017.3448

Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When is the Most Clinically Relevant Time to Evaluate?—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(12):1397-1398. doi:10.1001/jamacardio.2017.3458

Safety vs Efficacy of Lowering Blood Pressure

Abstract Full Text
JAMA Cardiol. 2017;2(12):1398-1399. doi:10.1001/jamacardio.2017.3534

Safety vs Efficacy of Lowering Blood Pressure

Abstract Full Text
JAMA Cardiol. 2017;2(12):1398. doi:10.1001/jamacardio.2017.3537

Safety vs Efficacy of Lowering Blood Pressure—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(12):1399-1400. doi:10.1001/jamacardio.2017.3543

Safety vs Efficacy of Lowering Blood Pressure—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(12):1400. doi:10.1001/jamacardio.2017.3540
Editor's Note

Race/Ethnicity–Based Outcomes in Cardiovascular Medicine

Abstract Full Text
has audio
JAMA Cardiol. 2017;2(12):1313-1314. doi:10.1001/jamacardio.2017.3826
JAMA Cardiology Patient Page

I Have High Blood Pressure: What Do I Need to Know?

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1404. doi:10.1001/jamacardio.2017.4126

This article outlines steps to prevent and manage high blood pressure.

JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2017;2(12):1292. doi:10.1001/jamacardio.2016.3680
×